Insmed (INSM) Launches BRINSUPRI In Japan, Is The Stock A Bargain?

Insmed (INSM) is back in focus after two fresh catalysts. The group has launched BRINSUPRI Tablets in Japan for non cystic fibrosis bronchiectasis and added experienced biopharma leaders Paul Hudson and Utpal Koppikar to its board.

Recent trading has been weak for Insmed, with the share price down 21.08% over the past month and 47.27% year to date to US$93.39, even though long term total shareholder returns over three and five years remain very strong. This suggests recent momentum has faded as investors reassess both growth potential and execution risks around the expanding pipeline and new product launches.

Capitalize on the renewed focus on rare disease treatments around Insmed by scanning a handpicked 21 high quality undiscovered gems that could be next in line for attention.

Insmed now trades at a steep discount to both analyst targets and some intrinsic estimates after that sharp pullback. Is the market sensibly pricing execution risk, or is caution starting to look excessive?

Most Popular Narrative: 53% Undervalued

On the most followed narrative, Insmed's fair value sits at $197.14 per share, well above the last close of $93.39. This puts a lot of weight on how its rare disease portfolio and future launches play out.

The anticipated U.S. launch of brensocatib in bronchiectasis in the third quarter of 2025 is a major catalyst, expected to significantly increase revenue once it hits the market and starts generating sales late in Q3. The upcoming Phase II data for TPIP in PAH by mid-2025 and brensocatib in CRS without nasal polyps by the end of 2025 are key clinical milestones that could enhance future revenue streams if positive.

See why 21 investors see Insmed as 53% undervalued.

The fair value in that storyline uses a 7.17% discount rate and assumes revenue expanding at about 70.45% a year with margins reaching roughly 24.8%. This is an assertive set of inputs for a business that still reported a loss of $875.3m on revenue of $1.14b. Analysts in that framework also project earnings growth of around 67.4% a year and a future P/E near 56.1x, so the implied upside relies on Insmed turning current high investment in R&D and commercial build out into sustained profitability.

Against the $93.39 share price, that $197.14 fair value and our $374 future cash flow value estimate both point to a wide valuation gap, even though Insmed currently carries a P/S of 17.9x that screens above its fair P/S of 16.9x and the US Biotechs industry average of 11.1x. For investors, the key question is whether forecast high revenue growth and a forecast return on equity of 25.8% in three years are realistic enough to offset present losses, recent share underperformance and risks around funding, insider selling and execution on multiple late stage programs.

Result: Fair Value of $197.14 (UNDERVALUED)

Still, a setback in FDA timing for brensocatib, or tougher payer terms that slow real world uptake, could quickly challenge the bullish Insmed narrative investors are leaning on.

Find out about the key risks to this Insmed narrative.

Another View: What Insmed’s P/S Ratio Is Telling You

Insmed appears cheap on a narrative fair value of $197.14 per share, yet its P/S of 17.9x is higher than both its 16.9x fair ratio and the 11.1x US Biotechs benchmark and 8x peer average. That premium raises a simple question for you: Is the valuation risk worth the story?

Before relying on those richer sales multiples, it helps to see how they compare in a fuller breakdown of expectations and assumptions. You can review that in the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Conflicted by bullish narratives and visible risks around Insmed's story? Use that tension as a prompt to move quickly and test the underlying data yourself, starting with 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Insmed?

Do not stop with Insmed alone. Broaden your watchlist with focused stock ideas built from hard numbers, not hype, using these targeted screens.

• Zero in on quality at a discount by reviewing companies on the 27 high quality undervalued stocks that pair strong fundamentals with attractive pricing.
• Prioritise resilience by scanning the 30 resilient stocks with low risk scores to spot businesses that score well on stability and capital protection.
• Strengthen your core holdings by using the list of solid balance sheet and fundamentals (25 results) to find enterprises backed by cleaner debt profiles and sturdier finances.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com